COPYRIGHT© 2018 吉林紫鑫药业股份有限公司
Continuous improvement of standards, leading Chinese medicine to the world
The Chinese Medicine Law of the People's Republic of China will be officially implemented on July 1, which will surely become a milestone in the development of Chinese medicine. Yesterday (June 24th), the Executive Vice President of the Chinese Academy of Chinese Medical Sciences and Academician Huang Qiqi of the Chinese Academy of Engineering pointed out at the 19th Annual Meeting of the Chinese Association of Science and Technology that the main theme of contemporary Chinese medicine is innovation and development. In recent years, Chinese medicine standards have been constantly Improvement has begun to lead Chinese medicine to the world.
Academician Huang Yiqi said, "The current state of development of the Chinese herbal medicine industry is consistent with the country's economic development, that is, the growth rate has gradually decreased from the past 20% to 5.69% in 2015. The Chinese herbal medicines have fallen from the past 27% to Less than 8% in 2015, it also faces a shift period of structural adjustment and growth."
How to do the Chinese medicine industry in this period? Academician Huang Yiqi believes that it is necessary to firmly grasp the core engine of the development of the Chinese patent medicine industry in the large variety of Chinese herbal medicines. According to statistics, the current 216 cardiovascular and cerebrovascular drugs contained in the medical insurance catalogue, the top 30 varieties of sales, accounting for 84% of the sales of 216 varieties, that is to say, more than 80% of sales are from the top 30 varieties.
To carry forward and develop the cause of Chinese medicine, we must have a material basis. First, we must find out the resources of Chinese herbal medicines. To this end, starting from November 11, 2010, the research team he led carried out a survey of Chinese medicine resources in 922 counties across the country. At present, he has obtained information on the types of more than 13,000 kinds of medicinal plants, and collected 150,000 specimens. 49 new species were discovered and 29 monographs were published.
“Now, we have established 28 seedling breeding bases in 20 provinces and autonomous regions, conducted seed research on 120 kinds of Chinese herbal medicines, and established 28 provincial centers and 65 monitoring stations, 160 kinds of traditional Chinese medicines. The production, quality, circulation and reserves of timber were monitored and monitored. Jilin Province took the lead in realizing the comprehensive coverage of drug resources in the county, and the general survey of resources, we have mastered the information of 1564 kinds of traditional Chinese medicine resources in Jilin Province, and formulated 52 counties. Chinese herbal medicine industry development plan" Academician Huang Yiqi said, "Since the Chinese herbal medicine industry is an intensive resource of natural resources, labor-intensive resources, capital-intensive resources and knowledge-intensive resources, it covers agriculture, manufacturing, wholesale and retail, and warehousing. Industry, science and technology and many other aspects, the long industrial chain, comprehensive driving, and the importance of agriculture, rural areas and farmers have become an important direction for cultivating new health industries, promoting regional economic development and poverty alleviation." Many places now regard Chinese herbal medicines as development. An important catcher of the economy, for example, Jilin is a province of Chinese herbal medicine industry, and Zhejiang is an economically developed province. Also proposes a "Zhejiang Bawei" genuine medicine development plan, in Yunnan Province, formerly rural main cash crop is tobacco, now thirty-seven industry has gradually developed.
At present, the research team of Academician Huang Yiqi has supported the establishment of 25 traditional Chinese medicine modern science and technology industrial bases, focusing on the development of large varieties of Chinese medicinal materials such as ginseng, notoginseng, licorice, and alfalfa, while ginseng is the “top priority”. According to statistics, among the top 100 varieties of proprietary Chinese medicines, ginseng ranked first, and among the 100 proprietary Chinese medicines, 17 were medicinal to ginseng, so ginseng is the engine for the development of Jilin traditional Chinese medicine industry. As of 2015, the output value of ginseng in Jilin Province is as high as 46 billion (including the development of ginseng food and cosmetics).
Academician Huang Yiqi particularly emphasized that to strengthen and strengthen the Chinese medicine industry, it is necessary to strengthen the standardization of Chinese medicine. With the promulgation and formulation of the Medium and Long-Term Development Plan for Chinese Medicine Standardization (2011-2020), five national standard technical committees corresponding to traditional Chinese medicine, acupuncture, Chinese medicine, Chinese and Western medicine, and Chinese medicine diagnosis and treatment have also been established. These have greatly promoted the improvement of the standard of traditional Chinese medicine in traditional Chinese medicine, from 10 in 2015 to 52 in 2016, a large increase.
Academician Huang Yiqi revealed that the establishment of these standards has begun to lead Chinese medicine to the world. "For example, 27 quality standards of 9 varieties including Danshen, Sanqi and Ganoderma lucidum have been officially adopted by the United States Pharmacopoeia. 99 Chinese medicine varieties are being reviewed and approved by the United States Pharmacopoeia, and 5 kinds of Chinese medicines have been included. The United States last supplemented the Code. In the "EU Pharmacopoeia", five varieties were included. The research team led by Researcher Wang Yingping also successfully used the ISO platform to develop international standards for ginseng seed seedlings. In addition, one-time use The international standard for sterile acupuncture needles has also been established.” Academician Huang Qiqi said, “The entry of these APIs into the corresponding national pharmacopoeia and the development of international standards has actually laid a good foundation for the entry of Chinese medicine in the future.”